EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Clinical Pharmacology of Oral Octreotide Capsules for the Treatment of Acromegaly

Meliha Melin Uygur, Marta Villanova, Stefano Frara, Andrea Giustina

touchREVIEWS in Endocrinology · 2024

DOI: 10.17925/ee.2024.20.1.9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift touchREVIEWS in Endocrinology, 2024. Verfasst von Meliha Melin Uygur und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Endocrine and Metabolic Sciences, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The primary goal of acromegaly treatment is to normalize biochemical parameters as it significantly reduces the risks of complications and comorbidities associated with the disease. First-line medical treatment is commonly represented by injectable somatostatin analogues (SRLs) after surgery. In June 2020, with the integration of Transient Permeation Enhancer® technology, oral octreotide capsules (OOCs) received regulatory approval from the US Food and Drug Administration for long-term maintenance treatment in patients with acromegaly who have responded to and tolerated treatment with octreotide or lanreotide. We reviewed the clinical pharmacological data on the development and clinical use of OOCs. The pharmacokinetic and pharmacodynamic data on OOCs showed a dose-dependent increase in octreotide levels and remarkable suppression of growth hormone secretion. The efficacy and safety of OOCs were investigated in four clinical trials conducted on patients with complete or partially controlled acromegaly. The trials resulted in the maintenance of biochemical control after switching from injectable SRLs to OOCs, with a comparable side-effect profile. Moreover, the acromegaly symptoms improved in patients on OOC. The data showed a patient preference to continue in the OOC arm for the extension phase of the trials. From the clinical pharmacological perspective, oral formulation of octreotide has the advantage of efficacy and safety with respect to injectable octreotide.

Schlagwörter

Stichwörter der Autor:innen

AcromegalyPituitary Tumor Centers of Excellence (PTCOE)efficacyinjectable somatostatin ligandsoral octreotide capsules (OOC)patient adherencequality of lifesomatostatin analoguestherapytransient permeation enhancer

Autor:innen und Institutionen

  • Institute of Endocrine and Metabolic Sciences, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy.
  • Department of Endocrinology and Metabolism Disease, School of Medicine, Recep Tayyip Erdogan University, Rize, Turkey.

Zitieren

APA

Uygur, M. M., Villanova, M., Frara, S., & Giustina, A. (2024). Clinical Pharmacology of Oral Octreotide Capsules for the Treatment of Acromegaly. touchREVIEWS in Endocrinology. https://doi.org/10.17925/ee.2024.20.1.9

Vancouver

Uygur MM, Villanova M, Frara S, Giustina A. Clinical Pharmacology of Oral Octreotide Capsules for the Treatment of Acromegaly. touchREVIEWS in Endocrinology. 2024. doi:10.17925/ee.2024.20.1.9

BibTeX
@article{Uygur2024,
  author = {Uygur, Meliha Melin and Villanova, Marta and Frara, Stefano and Giustina, Andrea},
  title = {Clinical Pharmacology of Oral Octreotide Capsules for the Treatment of Acromegaly},
  journal = {touchREVIEWS in Endocrinology},
  year = {2024},
  doi = {10.17925/ee.2024.20.1.9}
}
Kostenlos starten →